| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'13 | |
|---|---|---|---|---|---|---|
Operating Activities | ||||||
Net loss | ||||||
15,424 | -12,951 | -92 | 4,522 | -38,321 | -14,227 | |
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||
Depreciation and amortization | ||||||
6,306 | 6,264 | 5,482 | 4,722 | 4,267 | 1,157 | |
Amortization of lease right-of-use assets | ||||||
3,557 | - | - | - | - | - | |
Deferred income tax benefit | ||||||
-66,306 | - | - | - | - | - | |
Loss on disposal of fixed assets | ||||||
-430 | -156 | -6 | -40 | - | - | |
Stock-based compensation | ||||||
36,393 | 25,704 | 17,592 | 8,786 | 7,889 | 1,346 | |
Change in fair value of cash settled stock options | ||||||
3,088 | - | - | - | - | - | |
Loss on deconsolidation of DOSE | ||||||
- | - | - | - | -25,685 | - | |
Loss on extinguishment of debt | ||||||
- | - | - | - | -186 | - | |
Change in fair value of stock warrant liability | ||||||
- | - | - | -43 | 1,132 | -271 | |
Unrealized foreign currency losses | ||||||
-194 | -1,647 | 951 | -368 | -192 | - | |
Accrued interest expense | ||||||
- | - | - | - | - | 44 | |
Amortization of premium on short-term investments | ||||||
- | - | - | - | 51 | 106 | |
Amortization of discount on short-term investments | ||||||
-338 | -295 | 20 | 210 | 15 | - | |
Other liabilities | ||||||
5,352 | 1,919 | 722 | -31 | -91 | 20 | |
Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | ||||||
6,632 | 2,252 | 2,181 | 6,791 | 2,163 | 2,340 | |
Inventory, net | ||||||
-4,078 | 2,303 | 4,162 | 2,935 | 1,848 | 938 | |
Prepaid expenses and other current assets | ||||||
-917 | -1,756 | 494 | -1,762 | -755 | 164 | |
Accounts payable and accrued liabilities | ||||||
779 | 2,527 | 9,741 | 5,096 | 1,518 | 2,037 | |
Deferred tax asset and receivable, net | ||||||
- | - | 235 | - | - | - | |
Other assets | ||||||
1,777 | -204 | 345 | -127 | 127 | 35 | |
Net cash (used in) provided by operating activities | ||||||
-400 | 18,900 | 26,091 | 12,309 | -2,188 | -13,305 | |
Investing activities | ||||||
Purchases of short-term investments | ||||||
80,388 | 93,696 | 94,307 | 75,192 | 69,751 | 10,817 | |
Proceeds from sales and maturities of short-term investments | ||||||
80,494 | 78,851 | 88,891 | 55,354 | - | 10,711 | |
Cash acquired due to acquisition | ||||||
49,652 | - | - | - | - | - | |
Purchases of property and equipment | ||||||
4,724 | 10,315 | 6,311 | 6,278 | 877 | 852 | |
Purchase of iDOSE product line and related assets from DOSE Medical | ||||||
- | - | - | - | 15,000 | - | |
Investment in company-owned life insurance | ||||||
1,608 | 1,240 | 663 | - | - | - | |
Net cash provided by (used in) investing activities | ||||||
43,426 | -26,400 | -12,390 | -26,116 | -85,628 | -958 | |
Proceeds from exercise of stock options | ||||||
15,064 | 18,654 | 3,699 | 6,059 | 1,734 | 162 | |
Proceeds from issuance of Series F Preferred stock | ||||||
- | - | - | - | - | 19,227 | |
Proceeds from share purchases under Employee Stock Purchase Plan | ||||||
3,388 | 3,509 | 968 | 1,945 | 1,161 | - | |
Payment of employee taxes related to vested restricted stock units | ||||||
5,601 | 587 | - | - | - | - | |
Payment of debt assumed on the Avedro Merger | ||||||
22,496 | - | - | - | - | - | |
Proceeds from public offering, net of issuance costs | ||||||
- | - | - | - | 113,589 | - | |
Proceeds from senior secured term and draw-to term loans | ||||||
- | - | - | - | 6,852 | - | |
Payments of senior secured term and draw-to term loans | ||||||
- | - | - | - | 7,000 | - | |
Proceeds from line of credit | ||||||
- | - | - | - | 1,750 | - | |
Payments of line of credit | ||||||
- | - | - | - | 3,600 | - | |
Payments of subordinated notes | ||||||
- | - | - | -9,696 | -7,804 | - | |
Proceeds from exercise of stock warrants | ||||||
- | - | - | 50 | 428 | - | |
Net cash provided by financing activities | ||||||
-9,645 | 21,576 | 4,667 | -1,642 | 107,110 | 19,257 | |
Effect of exchange rate changes on cash and cash equivalents | ||||||
-252 | 48 | -434 | 371 | -26 | 2 | |
Net (decrease) increase in cash, cash equivalents and restricted cash | ||||||
33,160 | 14,088 | 17,934 | -15,078 | 19,268 | 4,996 | |
Supplemental schedule of noncash investing and financing activities | ||||||
Shares issued and Replacement Awards assumed in connection with Avedro Merger | ||||||
437,751 | - | - | - | - | - | |
Debt assumed in the Avedro Merger | ||||||
22,496 | - | - | - | - | - | |
Purchase of property and equipment included in accounts payable and accrued liabilities | ||||||
995 | 152 | 749 | - | - | - | |
Purchase of intangible asset in exchange for issuance of subordinated note | ||||||
- | - | - | - | - | 17,500 | |
Purchase of intangible assets in exchange for future payments | ||||||
- | - | - | - | 243 | - | |
Conversion of convertible notes and accrued interest into Series F convertible preferred stock | ||||||
- | - | - | - | - | 10,773 | |
Conversion of preferred stock into common stock | ||||||
- | - | - | - | 159,077 | - | |
Reduction of liability upon vesting of stock options previously exercised for unvested stock | ||||||
- | - | 4 | 62 | 86 | 11 | |
Payments to acquire treasury stock | ||||||
- | - | - | - | - | 132 | |
Supplemental disclosures of cash flow information | ||||||
Taxes paid | ||||||
171 | 401 | 12 | 513 | 25 | 4 | |
Interest paid | ||||||
2 | - | - | 285 | 834 | 75 | |